Neuroendocrine Cancer Market 20262031
The Neuroendocrine Cancer Market was valued at in and is anticipated to reach by 2031, at a CAGR of 0.106 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Neuroendocrine Cancer Market.
This report delivers a comprehensive overview of the Neuroendocrine Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuroendocrine Cancer Market. The Neuroendocrine Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –2031.
Neuroendocrine Cancer Market Scope:
By Drug Type
This report delivers a comprehensive overview of the Neuroendocrine Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuroendocrine Cancer Market. The Neuroendocrine Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Neuroendocrine Cancer Market.
This report delivers a comprehensive overview of the Neuroendocrine Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuroendocrine Cancer Market. The Neuroendocrine Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –2031.
Neuroendocrine Cancer Market Scope:
By Drug Type
- Sunitinib Malate
- Everolimus
- Lanreotide
- Octreotide
- Others
- Surgery
- Chemotherapy
- Targeted Therapy
- Radiotherapy
- Others
- Hospitals
- Oncology Centers
- Ambulatory Surgical Center
- Others
- Novartis AG
- Pfizer Inc.
- Ipsen
- Tarveda Therapeutics
- Progenics Pharmaceuticals, Inc.
- Hutchison Medipharma Limited
- Dauntless Pharmaceuticals Inc.
- Exelixis, Inc.
- Advanced Accelerator Applications
- Argos Therapeutics Inc(LIST NOT EXHAUSTIVE)
This report delivers a comprehensive overview of the Neuroendocrine Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Neuroendocrine Cancer Market. The Neuroendocrine Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing research and development and the growing prevalence of neuroendocrine cancer are expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. The side effects associated with neuroendocrine cancer treatment are expected to hamper the market.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Unmet Needs
5.2. Supply Chain
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type Segment
7.2. Sunitinib Malate*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Everolimus
7.4. Lanreotide
7.5. Octreotide
7.6. Others
8. BY TREATMENT
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment Segment
8.2. Surgery*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Chemotherapy
8.4. Targeted Therapy
8.5. Radiotherapy
8.6. Others
9. BY END USER
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
9.1.2. Market Attractiveness Index, By End user Segment
9.2. Hospitals*
9.2.1.1. Introduction
9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Oncology Centers
9.4. Ambulatory Surgical Center
9.5. Others
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales
10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
12. COMPANY PROFILES
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Pfizer Inc.
12.3. Ipsen
12.4. Tarveda Therapeutics
12.5. Progenics Pharmaceuticals, Inc.
12.6. Hutchison Medipharma Limited
12.7. Dauntless Pharmaceuticals Inc.
12.8. Exelixis, Inc.
12.9. Advanced Accelerator Applications
12.10. Argos Therapeutics Inc(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing research and development and the growing prevalence of neuroendocrine cancer are expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. The side effects associated with neuroendocrine cancer treatment are expected to hamper the market.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Unmet Needs
5.2. Supply Chain
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type Segment
7.2. Sunitinib Malate*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Everolimus
7.4. Lanreotide
7.5. Octreotide
7.6. Others
8. BY TREATMENT
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment Segment
8.2. Surgery*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Chemotherapy
8.4. Targeted Therapy
8.5. Radiotherapy
8.6. Others
9. BY END USER
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
9.1.2. Market Attractiveness Index, By End user Segment
9.2. Hospitals*
9.2.1.1. Introduction
9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Oncology Centers
9.4. Ambulatory Surgical Center
9.5. Others
10. BY REGION
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales
10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11. COMPETITIVE LANDSCAPE
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
11.4. List of Key Companies to Watch
12. COMPANY PROFILES
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Pfizer Inc.
12.3. Ipsen
12.4. Tarveda Therapeutics
12.5. Progenics Pharmaceuticals, Inc.
12.6. Hutchison Medipharma Limited
12.7. Dauntless Pharmaceuticals Inc.
12.8. Exelixis, Inc.
12.9. Advanced Accelerator Applications
12.10. Argos Therapeutics Inc(*LIST NOT EXHAUSTIVE)
13. DATAM INTELLIGENCE
13.1. Appendix
13.2. About Us and Applications
13.3. Contact Us
